Zobrazeno 1 - 10
of 100
pro vyhledávání: '"John L Niles"'
Publikováno v:
RMD Open, Vol 9, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/bed4d92bf23546999b079218cce01664
Autor:
Laura Yockey, Sarah Dowst, Reza Zonozi, Noah Huizenga, Patrick Murphy, Karen Laliberte, Jillian Rosenthal, John L. Niles, Caroline M. Mitchell
Publikováno v:
BMC Women's Health, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Consequences of long-term B cell depletion with rituximab are not well understood. We describe inflammatory vaginitis as a potential side effect of long-term rituximab treatment, distinct from previously described vulvovaginal pyo
Externí odkaz:
https://doaj.org/article/e0b92346ab0549df96dc85abd8fc602b
Autor:
Noah Huizenga, Reza Zonozi, Jillian Rosenthal, Karen Laliberte, John L. Niles, Frank B. Cortazar
Publikováno v:
Kidney International Reports, Vol 5, Iss 4, Pp 542-545 (2020)
Externí odkaz:
https://doaj.org/article/a26a1a1c37404596a7934e218a20367e
Autor:
Frank B. Cortazar, Saif A. Muhsin, William F. Pendergraft, III, Zachary S. Wallace, Colleen Dunbar, Karen Laliberte, John L. Niles
Publikováno v:
Kidney International Reports, Vol 3, Iss 2, Pp 394-402 (2018)
Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab wit
Externí odkaz:
https://doaj.org/article/5af4cb56878d4e5db1e0d46f2924971b
Autor:
Frank B. Cortazar, Sujal I. Shah, Astrid Weins, John L. Niles, Reza Zonozi, Pravarut Nithagon, Anushya Jeyabalan, Karen Laliberte
Publikováno v:
Kidney International Reports
Anti−glomerular basement membrane (anti-GBM) disease is characterized by pathogenic autoantibodies targeting the α-3 chain of type IV collagen located in the glomerular and alveolar basement membranes. Clinically, it causes rapidly progressive glo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f163a7374927dc8fd5f43e146f73fc5
https://doi.org/10.1016/j.ekir.2021.07.001
https://doi.org/10.1016/j.ekir.2021.07.001
Autor:
Peter A. Merkel, John L. Niles, Lester E. Mertz, Patricia B. Lehane, Pooneh Pordeli, Félix Erblang, Nancy Allen, Joel A. Block, Rodrigo Cartin‐Ceba, Curry Koening, Carol Langford, Paul Monach, Larry W. Moreland, Patrick Nachman, Daniel Wallace
Publikováno v:
Arthritis Care & Research
Objective The present study was undertaken to conduct a phase IV, open‐label, prospective study to characterize the long‐term safety of rituximab in a 4‐year observational registry of adult patients with granulomatosis with polyangiitis (GPA) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::169c4721c565f2806d5d8d5bd88aebd6
https://doi.org/10.1002/acr.24332
https://doi.org/10.1002/acr.24332
Publikováno v:
Kidney International Reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbb6520c5b4037da5e4e6f274cfe2606
https://doi.org/10.1016/j.ekir.2021.03.001
https://doi.org/10.1016/j.ekir.2021.03.001
Autor:
Noah Huizenga, Karen Laliberte, Zachary S. Wallace, Jillian Rosenthal, Reza Zonozi, Eugene P. Rhee, Frank B. Cortazar, John L. Niles
Publikováno v:
Arthritis & Rheumatology. 73:347-354
OBJECTIVE Late-onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence. METHODS We conducted a single-center ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4def1436f41b1310a3ace6dc44d88fa
https://doi.org/10.1002/art.41501
https://doi.org/10.1002/art.41501
Autor:
Thomas J. Schall, Pirow Bekker, Classic Investigators, Andrew S. Bomback, Brad H. Rovin, Christian Pagnoux, John L. Niles, Robert Spiera, Antonia Potarca, Peter A. Merkel, Richard A.H. Jimenez
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 11, Pp 662-671 (2020)
ACR Open Rheumatology
ACR Open Rheumatology
Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa9fed80daebe87ee4df42e0f5585432
https://doi.org/10.1002/acr2.11185
https://doi.org/10.1002/acr2.11185
Autor:
Karen Laliberte, Noah Huizenga, Jillian Rosenthal, Reza Zonozi, John L. Niles, Frank B. Cortazar
Publikováno v:
Kidney International Reports, Vol 5, Iss 4, Pp 542-545 (2020)
Kidney International Reports
Kidney International Reports
Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is a small vessel necrotizing vasculitis with a predilection for the respiratory tract and kidneys.1,2 Prompt initiation of remission induction immunosuppression is paramount to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5f9b564ecb6bb312aba1692ca9390f
http://www.sciencedirect.com/science/article/pii/S2468024919315621
http://www.sciencedirect.com/science/article/pii/S2468024919315621